Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 2, 2004, Pages 171-181

  Layton, D ^a,b   Heeley, E ^a   Shakir, S A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Colitis; Pharmacovigilance; Rofecoxib; Signal generation

Indexed keywords

ETODOLAC; IBUPROFEN; MELOXICAM; NABUMETONE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; TENOXICAM;

ADULT; AGED; ARTICLE; COLITIS; CONTROLLED STUDY; DATA BASE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MALE; MATHEMATICAL COMPUTING; PRESCRIPTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOMATIC DATA PROCESSING; COHORT STUDIES; COLITIS; DRUG MONITORING; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; LACTONES; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PRIMARY HEALTH CARE; STATE MEDICINE; SULFONES;

EID: 1842734427     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2004.00550.x     Document Type: Article

References (28)

1. Mann RD (1998) Prescription-event monitoring-recent progress and future horizons. British Journal of Clinical Pharmacology, 46, 195-201.
2. Shakir SA (2002) PEM in the UK. In: Mann RD, Andrews E, eds. Pharmacovigilance. Chichester, UK: John Wiley & Sons, 333-344.
3. Legemaate J (1994) The CIOMS guidelines for biomedical research involving human subjects. European Journal of Health Law, 1, 161-165.
4. Machin D, Campbell M, Fayers P et al. (1997) Sample size tables for clinical studies. Oxford, UK: Blackwell Science Ltd.
5. Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiological Drug Safety, 10, 483-486.
6. Heeley E, Wilton LV, Shakir SA (2002) Automated signal generation in prescription-event monitoring. Drug Safety, 25, 423-432.
7. Hauben M, Zhou X (2003) Quantitative methods in pharmacovigilance: focus on signal detection. Drug Safety, 26, 159-186.
8. Layton D, Riley J, Wilton LW, Shakir S (2002) Safety profile of rofecoxib as used in general practice in England: results of a Prescription-Event monitoring study. British Journal of Clinical Pharmacology, 55, 166-174.
9. MSD (1999) Summary of product characteristics; Vioxx.
10. Kaufmann HJ, Taubin HL (1987) Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Annals of Internal Medicine, 107, 513-516.
11. Savage R (2001) Non-steroidal anti-inflammatory agents can cause lower gastrointestinal tract damage prescriber update articles NSAIAs can cause lower GIT damage. Prescriber Update, 21, 25-27.
12. Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM (1997) Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut, 40, 619-622.
13. Bonner GF (2001) Exacerbation of inflammatory bowel disease associated with use of celecoxib. American Journal of Gastroenterology, 96, 1306-1308.
14. Garcia B, Ramaholimihaso F, Diebold MD, Cadiot G, Thiefin G (2001) Ischaemic colitis in a patient taking meloxicam. Lancet, 357, 690.
15. Yarze JC (2001) Ischaemic colitis and meloxicam. Lancet, 357, 1619.
16. Freitas J, Farricha V, Nascimento I, Borralho P, Parames A (2002) Rofecoxib: a possible cause of acute colitis. Journal of Clinical Gastroenterology, 34, 451-453.
17. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, Bjarnason I (2000) COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut, 47, 527-532.
18. Parfitt K (1999) Martindale, 33rd Edn. London: Pharmaceutical Press.
19. Multi-Centre Research Ethics Committees Guidance Notes (2000) Examples of enquiries and surveys in the public interest where no reference to a Research Ethics Committee is necessary. p. 21.
20. Strom B (2000) Study designs available for pharmacoepidemiology studies. In: Strom B, ed. Pharmacoepidemiology. Chichester, UK: John Wiley & Sons Ltd., pp. 17-29.
21. Layton D, Heeley E, Hughes K, Shakir S (2003) Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology, 42, 622-631.
22. Wallace JL (2001) Prostaglandin biology in inflammatory bowel disease. Gastroenterology Clinics of North America, 30, 971-980.
23. Wallace JL (1997) Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology, 112, 1000-1016.
24. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL (1996) Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. Journal of Clinical Investigation, 98, 2076-2085.
25. Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology, 115, 297-306.
26. Ajuebor MN, Singh A, Wallace JL (2000) Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology, 279, G238-G244.
27. McCartney SA, Mitchell JA, Fairclough PD, Farthing MJ, Warner TD (1999) Selective COX-2 inhibitors and human inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 13, 1115-1117.
28. Bonner GF (2002) Using COX-2 inhibitors in IBD: anti-inflammatories inflame a controversy. American Journal of Gastroenterology, 97, 783-785.